PMVP
PMV Pharmaceuticals, Inc.
Healthcare — Biotechnology
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
None
3 analysts
$1.75
+$0.08 (+4.79%)
Target:
$4.33
(147.6%)
Price History
52-Week Range
Sign in to add PMVP to a watchlist or set price alerts.
Fundamentals
| Market Cap | $66.13M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.13 |
| EPS (TTM) | $-1.48 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -63.16% |
| Debt/Equity | 0.33 |
| Recommendation | None |
| Analyst Target | $4.33 |
| Analysts | 3 |
| Next Earnings | Aug 14, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 65.0 |
| Beta | 1.36 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.88 |
| 52-Week Low | $1.02 |
| 50-Day Avg | $1.26 |
| 200-Day Avg | $1.30 |
| Avg Volume | 372.9K |
| Volume | 252.4K |
Performance Analysis
BULLISHPMVP shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 85% of its 52-week range.
+
RSI at 65.0 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Wall Street consensus is "none" from 3 analysts.
+
Average analyst target of $4.33 implies 147.6% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report